In summary, IDH mutations result in profound metabolic reprogramming, which may provide a foundation for the development of targeted therapies aimed at exploiting these unique metabolic vulnerabilities in gliomas and other IDH-mutant cancers. The gene discussed is IDH2; the disease is glioma.